NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NCI E-213-2018-0-HK-09 TRITERPENE AMINE DERIVATIVES HK EP 62021037592.4 Pending
NCI E-098-2018-0-HK-07 T CELL RECEPTORS WHICH RECOGNIZE MUTATED EGFR HK EP 62021037536.1 Pending
NCI E-148-2011-0-US-52 ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III CHIMERIC ANTIGEN RECEPTORS AND USE OF SAME FOR THE TREATMENT OF CANCER US CON 17/410,129 11879017 Issued PDF
NIAID E-057-2011-2-US-06 VIRUS-LIKE PARTICLES AND METHODS OF USE US CON 17/410,182 11718647 Issued PDF
NCI E-109-2020-0-PCT-02 PREFERENTIAL GENERATION OF iPSC CARRYING ANTIGEN SPECIFIC TCRs FROM TUMOR INFILTRATING LYMPHOCYTES PCT PCT PCT/US2021/046969 Expired
NIAID E-297-2016-2-AU-08 VACCINE CANDIDATES FOR HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV) HAVING ATTENUATED PHENOTYPES AU DIV 2021218112 Issued
NCI E-029-2019-0-KR-09 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12R MUTATION KR National Stage 2021-7026169 Pending
NCI E-065-2016-0-US-05 COMBINATION OF HISTONE DEACETYLASE INHIBITOR AND IMMUNOTHERAPY US DIV 17/402,751 Abandoned
CC E-001-2019-1-US-02 HANDGRIP RELAXOMETER SYSTEM US National Stage 17/430,891 Pending
NCI E-029-2019-0-EP-07 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12R MUTATION EP National Stage 20705599.7 Pending
NEI E-195-2020-0-PCT-03 Sensitive And Economic RNA Virus Detection Using A Novel RNA Preparation Method PCT PCT PCT/US2021/045675 Expired
NINDS E-102-2019-1-CA-03 HIGH-RESOLUTION CEREBROSPINAL FLUID-SUPPRESSED T2*-WEIGHTED MAGNETIC RESONANCE IMAGING OF CORTICAL LESIONS CA National Stage 3130216 Pending
NIA E-013-2010-0-BR-17 THE USE OF FENOTEROL AND FENOTEROL ANALOGUES IN THE TREATMENT OF GLIOBLASTOMAS AND ASTROCYTOMAS BR DIV BR122021015782-0 Issued
NIAID E-105-2020-0-PCT-02 Replication-Competent Adenovirus Type 4-HIV Env Vaccines And Their Use PCT PCT PCT/US2021/045389 Expired
NCI E-107-2020-0-PCT-02 IGG4 HINGE-CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GLYPICAN-1 (GPC1) FOR TREATING SOLID TUMORS PCT PCT PCT/US2021/045305 Expired
NCI E-050-2014-0-EP-20 Cancer Immunotherapy by Delivering Class II MHC Antigens Using a VLP-Replicon EP DIV 21190529.4 Pending
NIAID E-099-2016-0-AU-21 USE OF GRAM NEGATIVE SPECIES TO TREAT ATOPIC DERMATITIS AU DIV 2021215132 Abandoned
NCATS E-200-2020-0-PCT-02 REAL-TIME CELLULAR THERMAL SHIFT ASSAY (RT-CETSA) FOR RESEARCH AND DRUG DISCOVERY PCT PCT PCT/US2021/045184 Expired
NCI E-053-2019-0-US-12 GENETICALLY MODIFIED HEMATOPOIETIC STEM AND PROGENITOR CELLS (HSPCS) AND MESENCHYMAL CELLS AS A PLATFORM TO REDUCE OR PREVENT METASTASIS, TREAT AUTOIMMUNE AND INFLAMMATORY DISORDERS, AND REBALANCE THE IMMUNE MILIEU AND DYSREGULATED NICHES US National Stage 17/429,391 Pending
NIAID E-147-2015-0-HK-16 BROADLY NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST HIV-1 V1V2 ENV REGION HK EP 42021036522.7 Pending
NCI E-053-2019-0-EP-11 GENETICALLY MODIFIED HEMATOPOIETIC STEM AND PROGENITOR CELLS (HSPCs) AND MESENCHYMAL CELLS AS A PLATFORM TO REDUCE OR PREVENT METASTASIS, TREAT AUTOIMMUNE AND INFLAMMATORY DISORDERS, AND REBALANCE THE IMMUNE MILIEU AND DYSREGULATED NICHES EP National Stage 20711371.3 Pending
NCI E-190-2014-0-US-42 VIRUS-LIKE PARTICLE CONJUGATES FOR DIAGNOSIS AND TREATMENT OF TUMORS US CON 17/395,369 11806406 Issued PDF
NCI E-053-2019-0-AU-08 GENETICALLY MODIFIED HEMATOPOIETIC STEM AND PROGENITOR CELLS (HSPCs) AND MESENCHYMAL CELLS AS A PLATFORM TO REDUCE OR PREVENT METASTASIS, TREAT AUTOIMMUNE AND INFLAMMATORY DISORDERS, AND REBALANCE THE IMMUNE MILIEU AND DYSREGULATED NICHES AU National Stage 2020219097 Pending
NEI E-212-2015-0-JP-09 METHOD FOR REPRODUCIBLE DIFFERENTIATION OF CLINICAL-GRADE RETINAL PIGMENT EPITHELIUM CELLS JP DIV 2021-128087 Pending
NIDCR E-129-2021-0-US-01 AQP1 Gene Therapy To Prevent Radiation Induced Salivary Hypofunction US 63/229,279 Abandoned
NCI E-148-2011-0-IL-51 Anti-Epidermal Growth Factor Receptor Variant III Chimeric Antigen Receptors And Use Of Same For The Treatment Of Cancer IL DIV 285335 Issued
CC E-183-2016-0-EP-11 DETECTION OF PROSTATE CANCER IN MULTI-PARAMETRIC MRI USING RANDOM FOREST WITH INSTANCE WEIGHTING & MR PROSTATE SEGMENTATION BY DEEP LEARNING WITH HOLISTICALLY-NESTED NETWORKS EP DIV 21189335.9 Pending
NINDS E-117-2021-0-US-01 D3 Dopamine Receptor-Selective Negative Allosteric Modulators. US 63/228,660 Abandoned
NCI E-048-2021-0-US-01 HIV-1 VACCINATION AND SAMT-247 MICROBICIDE TO PREVENT HIV-1 INFECTION US 63/228,707 Abandoned
NCI E-247-2015-0-US-08 IL-7R-ALPHA SPECIFIC ANTIBODIES FOR TREATING ACUTE LYMPHOBLASTIC LEUKEMIA US CON 17/392,075 Pending
NCATS E-232-2020-0-PCT-02 MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF PCT PCT PCT/US2021/044089 Expired
NCATS E-232-2020-0-EP-01 MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF EP National Stage 21849411.0 Pending
NCATS E-027-2021-0-PC-01 QUANTUM DOT CONJUGATED VIRUS SPIKE PROTEIN FOR CELL-BASED BIO-SENSING SYSTEMS AND DRUG SCREENING PCT PCT PCT/US2021/043846 Expired
NCI E-196-2018-0-PCT-02 INSERT FOR PREPARING CELL CULTURE CHAMBERS PCT PCT PCT/US2021/043930 Expired
NCATS E-027-2021-0-US-02 Quantum Dot Conjugated Virus Spike Protein For Cell-based Bio-sensing Systems And Drug Screening US ORD 17/389,645 Pending
NCI E-141-2008-0-US-35 Complexes Of IL-15 And IL-15R AIpha And Uses Thereof US CON 17/390,495 Pending
NCI E-230-2012-0-JP-64 T Cell Receptors Recognizing MHC Class II-Restricted Mage-A3 JP DIV 2021-124003 Issued
NCI E-107-2021-0-AU-01 Use Of TomentosenalA For Treatment Of Skin Conditions AU ORD 2021902329 Issued
NCATS E-004-2016-0-AU-01 SMALL MOLECULE BET BROMODOMAIN INHIBITORS AND USES THEREOF AU DIV 2021209257 Issued
NIAID E-052-2017-4-MY-56 Trispecific And/or Trivalent Binding Proteins For Prevention Or Treatment Of HIV Infection MY DIV PI 2021004277 Pending
NHLBI E-039-2022-0-US-01 TEMPERATURE CYCLING METHOD FOR HYPERPOLARIZATION OF TARGET MOLECULES AND CONTRAST AGENTS USING PARAHYDROGEN US 63/203,591 Abandoned
NHLBI E-045-2018-0-US-07 Vascular Anchoring Introducer Sheath US DIV 17/385,230 12011151 Issued PDF
NINDS E-201-2020-0-PCT-02 NANOBODIES DIRECTED TO CORONAVIRUS SPIKE PROTEIN RECEPTOR BINDING DOMAIN AND USES THEREOF PCT PCT PCT/US21/42883 Expired
NINDS E-201-2020-0-EP-03 NANOBODIES DIRECTED TO CORONAVIRUS SPIKE PROTEIN RECEPTOR BINDING DOMAIN AND USES THEREOF EP National Stage 21755255.3 Pending
NIBIB E-007-2021-1-US-01 ANTIBODY SPECIFIC FOR SARS-COV-2 RECEPTOR BINDING DOMAIN AND THERAPEUTIC METHODS US 63/225,248 Abandoned
NIAID E-089-2019-0-US-03 SIRPa EXPRESSION ON T CELLS IS A BIOMARKER FOR FUNCTIONAL T CELLS DURING EXHAUSTION US National Stage 17/425,224 Abandoned
CC E-103-2018-0-US-03 METHODS AND COMPOSITIONS FOR DETECTING TRANSFUSION-TRANSMITTED PATHOGENS US National Stage 17/425,228 Pending
NCI E-050-2014-0-CN-21 Cancer Immunotherapy by Delivering Class II MHC Antigens Using a VLP-Replicon CN DIV 202110829496.3 Abandoned
NIAID E-052-2017-0-TW-12 Trispecific Binding Protein TW DIV 110126977 Pending
NCI E-077-2017-0-US-05 CATIONIC LIPID VACCINE COMPOSITIONS AND METHODS OF USE US CON 17/382,446 Pending